Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
Rabia Miray Kisla EkinciSibel BalcıDilek KaragozDerya Ufuk AltintasMustafa YilmazPublished in: Paediatric drugs (2019)
Canakinumab may be an effective treatment option for pediatric FMF patients with colchicine resistance, renal amyloidosis, and chronic oligoarthritis. Further studies are needed to clarify the efficacy of canakinumab in patients with a second disease, RF-positive polyarticular juvenile idiopathic arthritis.